7,186 views
MTO WA MBU 28/10 LEO... NAMANGA 29/10 KESHO hakikisha haikupiti hii... Richard Martin @richmavoko atakuwa hapo kuhakikisha anakonga Roho yako...!!!!
- INAPATIKANA HAPA
- Ndondoshaaa
- Hatar
- Simbaa
Read More »
Read More »
Technical University Munich
Technische Universitaet Muenchen (TUM) is one of Europe’s leading universities. It has roughly 500 professors, 9,000 academic and non-academic staff (including those at the university hospital “Rechts der Isar”), and 36,000 students. It focuses on the engineering sciences, natural sciences, life sciences, medicine, and economic sciences. After winning numerous awards, it was selected as an “Elite University” in 2006 by the Science Council (Wissenschaftsrat) and the German Research Foundation (DFG). The university’s global network includes an outpost in Singapore. TUM is dedicated to the ideal of a top-level research based entrepreneurial university.
University of Munich
As one of Europe’s leading research universities, LMU Munich is committed to the highest international standards of excellence in research and teaching. Building on its 500-year-tradition of scholarship, LMU covers a broad spectrum of disciplines, ranging from the humanities and cultural studies through law, economics and social studies to medicine and the sciences. 14 percent of LMU‘s 50,000 students come from abroad, originating from 130 countries worldwide. The know-how and creativity of LMU’s academics form the foundation of the University’s outstanding research record. This is also reflected in LMU‘s designation of as a “university of excellence” in the context of the Excellence Initiative, a nationwide competition to promote top-level university research.
Tuzo za AFRIMMA ambazo hutolewa kila mwaka kwa Waafrika mbalimbali waliofanya vizuri kwenye sekta mbalimbali hasa za burudani, zimetolewa Dallas Texas Marekani leo ambapo kwenye list yote Watanzania walioshinda ni watatu.
Watanzania walioshinda ni Dj D Ommy wa CloudsFM kupitia show mbalimbali ikiwemoXXL na AMPLIFAYA ambapo ameshinda tuzo ya Dj bora Afrika, mwimbajiHarmonize akishinda tuzo ya msanii bora chipukizi Afrika 2016 hukuDiamond Platnumzakishinda ya msanii bora wa kiume Afrika Mashariki.
Sasa miongoni waliotoa pongezi kwa Harmonize ni Diamond Platnumza ambae kupitia instagram alipost picha na kuyaandika haya>>>>
I remember last year you came to receive me at the airport when I was coming from @afrimmaawards with my trophies…and you asked me “do you think one day I will even be nominated on any international Awards” then I told you “If you work hard, Praying hard, Believe in God, respecting everybody then God will make a way…. and today we are here celebrating Your BEST NEW COMER AFRICA Winning
… congrats @harmonize_tz and thanks a lot to our beloved fans and@Afrimma for keep supporting African talents…
… congrats @harmonize_tz and thanks a lot to our beloved fans and@Afrimma for keep supporting African talents…
(Hii picha inanikumbusha mwaka jana ulipokuja nipokea airport kutokea@afrimma …ukaniuliza “hivi ipo siku nami nitachaguliwa tunzo yoyote ya kimataifa”….nikakwambia “Ukifanya kazi kwa bidii, Ukimuheshimu kila mtu, ukamuamini na kumuomba Mwenyez Mungu basi Mollah atakufungulia ndoto zako….na leo hii kweli Tunafurahia Ushaindi wako wa Msanii Bora Chipkizi Africa….. Hongera sana @harmonize_tz na shukran sana sana kwa Mashabiki zetu pendwa kwa kura na @Afrimma kwa kuendelea kuvinyanyua vipajia vya Africa
)
)Heidelberg University – A Tradition for the Future
Established in 1386, Heidelberg University – also known as Ruperto Carola – is Germany’s oldest university and one of Europe’s most research-intensive institutions. Its successes in the Excellence Initiative and its internationally recognised rankings substantiate the leading role and excellent reputation of Heidelberg University in the academic, scientific and research landscape. In educating students and advancing outstanding young researchers, Ruperto Carola emphasises research-based teaching and structured doctoral training programmes in its graduate schools.Heidelberg University sees itself as a research university, and its broad subject spectrum includes the humanities, the social sciences, law, the natural and life sciences, and medicine. The four interdisciplinary Fields of Focus form the core of Heidelberg’s research strategy: the molecular and cellular basis of life, structure and pattern formation in the material world, cultural dynamics in globalised worlds, and self-regulation and regulation: individuals and organisations.
Over 30,000 students are enrolled in the twelve faculties of Ruperto Carola. With more than 160 degree programmes, Heidelberg offers a preeminent array of subject combinations. The university actively participates in a worldwide network of teaching and research collaborations. International graduate academies, 19 institutional partnerships at the overall university level, and exchange arrangements with over 400 universities throughout the world underscore the strength of Ruperto Carola’s international ties. One in five research associates comes from outside Germany, and the percentage of international fellows in the graduate academies often exceeds 50 percent.
The university is especially committed to advancing exceptional individual disciplines, promoting dialogue beyond traditional disciplinary boundaries, and turning research findings to good use for society and the economy. In this endeavour it relies on strong partners outside the university. Examples include the alliances in the life sciences with the German Cancer Research Centre in Heidelberg or the HEiKA alliance with the Karlsruhe Institute for Technology with its strong focus on the natural and engineering sciences.Pursuant to the Industry-on-Campus (IoC) concept, Ruperto Carola enters into longer-term cooperative partnerships with industry in strategically oriented basic research in order to improve knowledge transfer into application-oriented research. One such IoC organisation that enjoys international visibility is the Catalysis Research Laboratory, or CaRLa, in which university post-docs work together with BASF.
Adding to the lustre of Heidelberg’s international reputation as a quality research institution are its Nobel laureates. 56 Nobel prize winners are connected with Heidelberg, eleven of whom were or still are professors at the university. The most recent recipients were Stefan W. Hell in chemistry in 2014 and Harald zur Hausen in physiology or medicine in 2008.
Heidelberg’s cosmopolitan and student-friendly atmosphere is one of the city’s distinguishing characteristics. Heidelberg is a lively centre of the Rhine-Neckar metropolitan region and is marked by its high density of research-intensive industry and conglomeration of scientific research institutions. These institutions, working alongside the university, form an internationally competitive research network, providing a wide assortment of contact and cooperation possibilities for Heidelberg University researchers and students.
In its efforts to combine European university values such as autonomy, freedom of research and teaching, non-discriminatory access and meritocratic advancement structures with forward-looking academic concepts in research and teaching, Heidelberg University is architecting a bridge to the future – The Future. Since 1386.
Read More »
Masters Funding Overview
If you’re thinking about doing a Masters degree, then the chances are you’re also considering the cost of postgraduate study – and the funding available.Funding for Masters study can seem complex at first. As an undergraduate you may have been covered by a national grant or student loan scheme, offered to you as standard by your government. As a postgraduate you’ll have to be much more proactive in seeking out, evaluating and applying for funding from one of a wide range of sources.
The information in our funding guides will help you make sense of these different options and find the right funding for your Masters degree. You can also learn more about our own FindAMasters scholarships, as well as our dedicated postgraduate funding search tool.
Simply select a section below to help you get started:
Masters Funding Guides
As well as our detailed guides to Masters funding in the UK, we’ve put together information for students in a range of other countries around the world, from France to the USA. Each of these covers fees and funding for domestic and international Masters students. This section also includes our overview of the Erasmus+ programme – an important source of funding for postgraduate study abroad.FindAMasters.com scholarships
In addition to offering advice about different sources of postgraduate funding, FindAMasters.com is proud to offer postgraduate scholarships. For the sixth year running we’ll be giving away £12,000 of funding to prospective postgraduate students. To see full application details sign up to our newsletter.
BONYEZA HAPA CHINI KUANGALIA VIDEO YAKE!!
PostgraduateFunding.com
Our funding guides can help you understand how postgraduate funding works and our scholarship competition gives you a chance to win some, but did you know that we also offer a tool to help you find funding from a range of sources? Over at our sister-site, PostgraduateFunding.com, you can search for and compare thousands of Masters funding opportunities around the world.Read More »
Science and Technology
Our School brings together leading academics from a wide variety of backgrounds, working together to ensure that broad perspectives of systems are used, to challenge thinking and formulate approaches to science, engineering, psychology and analysis that are fit for purpose in our modern world.
Our first international campus
With its state-of-the-art facilities, impressive selection of courses and verdant, landscaped surroundings, our Dubai campus holds the distinction of being our first academic institution outside the United Kingdom.
We welcomed our inaugural cohort of students in January 2005, and we’re proud to have seen that number rise to more than 2,500 students of more than 90 different nationalities. During their course, our students gain internationally recognised British qualifications – as well as earn the exciting opportunity to study at our Hendon campus in London.
Kama wewe ni mfuatiliaji mzuri wa matukio ya fiesta, basi naamini utakuwa umekwisha kumsikia Platnumz akihojiwa kwenye kipindi cha jahazi cha clouds fm .
Diamond amesema kuwa mkataba wake na Kampuni ya Simu ya Vodacom ndio sababu inayomfanya asishiriki Fiesta mwaka huu.
Wadhamini wakuu wa Fiesta ni Tigo hivyo kufanya hivyo kutaleta mgongano wa maslahii kati ya kampuni hizo mbili.
Bonyeza link za picha za chini kusoma zaidi.
What do we teach?
Our courses in pre-undergraduate, undergraduate and postgraduate study span Accounting and Finance, Business and Management, Computing and IT, Education, Law and Politics, Marketing, Media and Communications, Psychology, Social Science and International Tourism Management. We also offer professional short courses to boost your career.
Exceptionally high academic standards worldwide
We achieved the highest possible endorsement from the UK’s Quality Assurance Agency for Higher Education. And those rigorous procedures apply to all of our academic courses, wherever they’re taught in the world.
If you study at our campus in Dubai, your course undergoes the same validation and monitoring system as the course our students in London enjoy – with the same exams taken simultaneously in both cities and identical Honours degrees awarded.
Inspirational surroundings – on and off campus
Our campus is set in the Knowledge Village, part of the Dubai Technology and Media Free Zone, and boasts an inspiring academic environment with its state-of-the-art, purpose-built facilities for student-centred learning. Outside of the classroom, you can find sports facilities, a bookshop, food court and prayer rooms – as well as plenty of commercial and retail outlets to choose from.
The surrounding areas also have much to contribute. Dubai stands as a modern, vibrant, cosmopolitan city with unprecedented economic growth, thanks to recent policies encouraging strategic commercial ventures. Many know it as a leading holiday destination – with its soaring temperatures and endless sunshine – where tourists can savour a peaceful, tolerant and multicultural setting against a backdrop of groundbreaking infrastructure and architecture.
In the School of Science and Technology, much of our work is guided by the notion that people have an essential part to play in modern engineering and technology. Within our School we are attempting to integrate the study of people, both as individuals and societies, with that of artefacts and the sciences that are involved.
Read More »
“It’s fear and lack of education,” Alice Police, a UC Irvine breast surgeon told the Orange County Register. “I just had a patient who came in … saying, ‘I want a bilateral (double mastectomy). I’m going to do everything I can to beat this cancer.’ It took me an hour to explain to her that it might hurt her.”
Early-stage breast cancer patients whose tumors carry genetic markers associated with a low risk of disease recurrence may not need chemotherapy, according to a new study that employed a test devised by UCSF researcher Laura van ’t Veer.
Using a genetic test known as MammaPrint, van ’t Veer and her colleagues were able to predict the risk of cancer recurrence by measuring the expression of a suite of 70 genes.
“For the first time, a prospective, randomized trial shows that the active biology of breast cancer in an individual, as assessed by the MammaPrint test, can assist in making a well-informed choice to undergo chemotherapy treatment or not,” said van ’t Veer.
An analysis of breast cancer isoforms developed at UCLA. Blue lines are associated with longer survival times, and magenta lines with shorter survival times.
Credit: Courtesy of Yi Xing/UCLA
Scientists also are working to help improve the accuracy of doctors’ prognoses for breast cancer patients.
To treat or not to treat? That is the question researchers at Lawrence Berkeley National Laboratory hope to answer with a new advance, identifying 14 genes that could help doctors and their cancer patients decide if a particular therapy would be worth pursuing.
Meanwhile, UC San Diego researchers reported that precision medicine can lead to better outcomes for patients with cancer. After reviewing 346 phase one clinical trials involving 13,203 patients, the study authors found that patients who received targeted treatments had response rates 6 times higher than those who did not.
New hope for patients
There have been other important advances, too.
UCLA scientists, led by Dennis Slamon, helped develop the breast cancer drug Herceptin – which the FDA approved in 1998 – and their research played a key role in the development of Ibrance, a new drug to treat patients with advanced breast cancer. After patients in a clinical study led by UCLA researchers showed a dramatic improvement using Ibrance, the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval last year.
UC Berkeley scientists recently found a target for treating one of the most deadly forms of breast cancer, known as “triple-negative” breast cancer. This form of breast cancer accounts for about 1 in 5 cases, and they are deadlier than other forms of breast cancer, in part because no drugs have been developed to specifically target these tumors.
Triple-negative breast cancers do not rely on the hormones estrogen and progesterone for growth, nor on human epidermal growth factor receptor 2 (HER2). Because they do not depend on these three targets, they do not respond to modern hormonal therapies or the HER2-targeted drug Herceptin.
In August, scientists announced that they had found a long-elusive Achilles’ heel within triple-negative breast tumors, and used a drug-lik molecule to successfully target this vulnerability, killing cancer cells in the lab and shrinking tumors in mice.
Such breakthroughs offer new hope to breast cancer patients. Courtney herself is now cancer-free, along with her three other family members.
“I am very grateful for the other problem solvers and entrepreneurs around the world who made that possible,” Courtney said.
Read More »
Early-stage breast cancer patients whose tumors carry genetic markers associated with a low risk of disease recurrence may not need chemotherapy, according to a new study that employed a test devised by UCSF researcher Laura van ’t Veer.
Using a genetic test known as MammaPrint, van ’t Veer and her colleagues were able to predict the risk of cancer recurrence by measuring the expression of a suite of 70 genes.
“For the first time, a prospective, randomized trial shows that the active biology of breast cancer in an individual, as assessed by the MammaPrint test, can assist in making a well-informed choice to undergo chemotherapy treatment or not,” said van ’t Veer.
An analysis of breast cancer isoforms developed at UCLA. Blue lines are associated with longer survival times, and magenta lines with shorter survival times.
Credit: Courtesy of Yi Xing/UCLA
Scientists also are working to help improve the accuracy of doctors’ prognoses for breast cancer patients.
 |
| Rayvanny and Chibu Dangote (7-10-16) |
Click kwenye picha ya chini / juu kuona nilichokuwa naangalia! Sio cha kitoto!!
A new method developed by UCLA scientists opens new avenues for doing just that, using data about patients’ genetic sequences to produce more reliable projections for survival time and how they might respond to possible treatments.
To treat or not to treat? That is the question researchers at Lawrence Berkeley National Laboratory hope to answer with a new advance, identifying 14 genes that could help doctors and their cancer patients decide if a particular therapy would be worth pursuing.
Meanwhile, UC San Diego researchers reported that precision medicine can lead to better outcomes for patients with cancer. After reviewing 346 phase one clinical trials involving 13,203 patients, the study authors found that patients who received targeted treatments had response rates 6 times higher than those who did not.
New hope for patients
There have been other important advances, too.
UCLA scientists, led by Dennis Slamon, helped develop the breast cancer drug Herceptin – which the FDA approved in 1998 – and their research played a key role in the development of Ibrance, a new drug to treat patients with advanced breast cancer. After patients in a clinical study led by UCLA researchers showed a dramatic improvement using Ibrance, the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval last year.
UC Berkeley scientists recently found a target for treating one of the most deadly forms of breast cancer, known as “triple-negative” breast cancer. This form of breast cancer accounts for about 1 in 5 cases, and they are deadlier than other forms of breast cancer, in part because no drugs have been developed to specifically target these tumors.
Triple-negative breast cancers do not rely on the hormones estrogen and progesterone for growth, nor on human epidermal growth factor receptor 2 (HER2). Because they do not depend on these three targets, they do not respond to modern hormonal therapies or the HER2-targeted drug Herceptin.
In August, scientists announced that they had found a long-elusive Achilles’ heel within triple-negative breast tumors, and used a drug-lik molecule to successfully target this vulnerability, killing cancer cells in the lab and shrinking tumors in mice.
Such breakthroughs offer new hope to breast cancer patients. Courtney herself is now cancer-free, along with her three other family members.
“I am very grateful for the other problem solvers and entrepreneurs around the world who made that possible,” Courtney said.
Read More »
Shortly after starting her Ph.D. program in integrative pathobiology at UC Davis, Angela Courtney was diagnosed with breast cancer. Three other members of her family received a similar diagnosis within that same year.
Courtney’s research focus became clear: Find a simple but effective test that would allow women to detect breast cancer in the early stages, when the chances of recovery are greatest.
Courtney, who completed her doctorate last year, has done just that, developing a urine test that could speed early detection of breast cancer. Not only is this method less expensive than a mammogram, it would let women avoid the radiation associated with those tests.
“Of course, this was a very difficult time for me, but the best way for me to cope with it was to look at it as a problem in need of a solution,” Courtney said. By detecting breast cancer early, “it won’t get to the stage and the point where radiation and chemotherapy and double mastectomies are needed.”
Courtney has teamed with UC Davis alum Michael Gilson. After winning an award at the UC Davis Big Bang business plan competition, they founded Adrastia Biotech in 2015 and are working to commercialize the urine test for detecting breast cancer.
Improved imaging
Read More »
Courtney’s research focus became clear: Find a simple but effective test that would allow women to detect breast cancer in the early stages, when the chances of recovery are greatest.
Courtney, who completed her doctorate last year, has done just that, developing a urine test that could speed early detection of breast cancer. Not only is this method less expensive than a mammogram, it would let women avoid the radiation associated with those tests.
 |
| Diamond Platnumz and ZariTheBosslady |
Courtney has teamed with UC Davis alum Michael Gilson. After winning an award at the UC Davis Big Bang business plan competition, they founded Adrastia Biotech in 2015 and are working to commercialize the urine test for detecting breast cancer.
Bofya hapa chini kuiona video yao
Courtney and Gilson are not alone. Scientists across the University of California system are taking aim at breast cancer. Along with developing better detection methods, researchers are making advances in imaging techniques and tapping into advances in genetics and immunology to develop more refined approaches to treatment.Improved imaging
Read More »
Today's Photos (as of 06 October 2016) of Diamond Platnumz with Rayvanny, Babutale and qBoymsafi.
Photos were taken before entering #Clouds_Fm for the enterview
Read More »
 |
| The men behind the trending song #SALOME, Diamond Platnumz and Rayvanny. |
 |
| BabuTale, qboymsafi, Rayvanny and Diamond Platnumz |
Read More »
Subscribe to:
Posts (Atom)
